Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Treatment with Fleeceflower Derivative Blocks Plaque Formation in Mouse Alzheimer's Disease Model

By BiotechDaily International staff writers
Posted on 26 Feb 2013
A compound derived from traditional Chinese herbal medicine prevented development of amyloid plaques when administered to young animals in a mouse model of Alzheimer's disease and reversed plaque formation when administered to older animals.

Investigators at the Capital Medical University (Beijing, China) worked with the APPV717I transgenic (Tg) mouse Alzheimer's disease model. In previous studies, these mice demonstrated cognitive impairments beginning at four months of age and developed amyloid plaques in the brain that were evident by 10 months.

In the current study Tg mice were treated with varying doses of tetrahydroxystilbene glucoside (TSG), the active compound derived from the Chinese herbal medicine tuber fleeceflower (Polygonum multiflorum Thunb). The drug was given to 4- or 10- month-old animals for a period of six months. At the end of the treatment, cDNA microarray analysis, reverse transcription PCR, western blotting, and immunochemical techniques were used to determine levels of alpha-synuclein messenger RNA (mRNA) and protein expression. Accumulation of alpha-synuclein leads to the formation of insoluble aggregates that have been implicated in several neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.

Results published in the January 2013 issue of the journal Restorative Neurology and Neuroscience revealed that alpha-synuclein mRNA expression increased in the hippocampus of four-month to 16-month old Tg mice compared with age-matched non-Tg controls. Alpha-synuclein protein expression in the hippocampus also increased significantly in four-month to 16-month old Tg mice. Significant down-regulation of alpha-synuclein mRNA and protein expression in the hippocampus was found after treatment with TSG for six months in both 10- and 16-month-old Tg mice. Production of dimers and tetramers of alpha-synuclein protein in Tg mice was inhibited after treatment with TSG.

The expression and aggregation of alpha-synuclein increased in an age-dependent fashion in Tg mice. TSG not only prevented over-expression of alpha-synuclein at an early stage, but also reversed the increased expression of alpha-synuclein and inhibited aggregation at the late stage of Tg mice. Therefore, TSG may have potential to prevent and treat Alzheimer's disease.

"Our results raise the possibility that TSG might be a novel compound for the treatment of Alzheimer's disease and dementia with Lewy body," said first author Dr. Lan Zhang, associate professor of pharmacology at Capital Medical University. "The role of alpha-synuclein, especially in the early phase of Alzheimer's disease, and its interaction with amyloid-beta should be considered when developing new therapeutic strategies to target Alzheimer's disease."

Related Links:

Capital Medical University



Channels

Genomics/Proteomics

view channel
Image: The osteochondroretricular stem cell is a newly identified type of bone stem cell that appears to be vital to skeletal development and may provide the basis for novel treatments for osteoarthritis, osteoporosis, and bone fractures. In this illustration of the head of a femur, osteochondroretricular stem cells are visualized in red (Photo courtesy of Dr. Timothy Wang, Columbia University).

Gremlin 1 Expression Distinguishes Stem Cells Able to Regenerate Bones and Cartilage in Adult Mice

A newly identified type of stem cell in the bone marrow of adult mice was found to be capable of regenerating both bone and cartilage. Investigators at Columbia University (New York, NY, USA) reported... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.